No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
NVO240726C129000
- 4.70
- +0.20+4.44%
15min DelayTrading Jul 22 09:50 ET
4.90High4.70Low
4.75Open4.50Pre Close20 Volume77 Open Interest129.00Strike Price9.60KTurnover36.98%IV1.09%PremiumJul 26, 2024Expiry Date3.26Intrinsic Value100Multiplier4DDays to Expiry1.44Extrinsic Value100Contract SizeAmericanOptions Type0.7566Delta0.0569Gamma31.68Leverage Ratio-0.2071Theta0.0121Rho23.97Eff Leverage0.0467Vega
Intraday
- 5D
- Daily
News
Hims & Hers Appoints Former Novo Nordisk President to Board
Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ
By David Wainer The two dominant players in the obesity market will eventually make way for a few more competitors. Just don't expect the latecomers to be equals to Eli Lilly and Novo Nordisk. There
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
By Adam Clark Eli Lilly and Novo Nordisk are sitting pretty in the pharmaceutical sector due to their weight-loss drugs. While the market has been nervous about potential competition, investors can
Novo Nordisk A/S - Share Repurchase Programme
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Up to 20% weight loss! Eli Lilly and Co's Theralogix (Tesofensine) approved in China, stronger effect than Sibutramine?
Is the competition intensifying?
Comments
$ROCHE HOLDING AG(RHHBY.US$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$ $Structure Therapeutics(GPCR.US$ $Viking Therapeutics(VKTX.US$ $Lipocine(LPCN.US$
📣 Roche News Snippet:
» CT-996 led to significant weight loss (-7.3%) after 4 weeks 🆚 placebo (-1.2%)
» data supports once-daily oral dosing regimen
» Safety profile was similar to other GLP-1 drugs; no unexpected safety issues observed
Did you see today's sell-off? 🔴
$Eli Lilly and Co(LLY.US$ $Novo-Nordisk A/S(NVO.US$ $Structure Therapeutics(GPCR.US$ $Viking Therapeutics(VKTX.US$ $Lipocine(LPCN.US$
5
Chip tensions
Global chip stocks tumbled amid potentially tighter restrictions on U.S. exports to China and escalating geopolitical tensions. U.S.-listed shares of ASML and Taiwan Semiconductor Manufacturing Co plunged 12% and 8%, respectively. The declines followed a Bloomberg report that the Biden administration is weighing tougher restrictions on companies exporting technology to China.
Nvidia shares slumped more than 6%, while Arm Holdings, Lam Research, Applied M...
Global chip stocks tumbled amid potentially tighter restrictions on U.S. exports to China and escalating geopolitical tensions. U.S.-listed shares of ASML and Taiwan Semiconductor Manufacturing Co plunged 12% and 8%, respectively. The declines followed a Bloomberg report that the Biden administration is weighing tougher restrictions on companies exporting technology to China.
Nvidia shares slumped more than 6%, while Arm Holdings, Lam Research, Applied M...
4
1
$Novo-Nordisk A/S(NVO.US$ Novo Nordisk receives Complete Response Letter in the US for Thomson Reuters (11/07/2024) Bagsværd, Denmark, 10 July 2024 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has issued a Complete
Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus. In the letter, the FDA has requests related to the manufac...
Response Letter (CRL) covering the Biologics License Application for once-weekly basal insulin icodec for the treatment of diabetes mellitus. In the letter, the FDA has requests related to the manufac...
2
Read more